James Rubenstein, MD, PhD, University of California San Francisco, San Francisco, CA, shares the findings of a study in which next-generation sequencing (NGS) was used to identify genomic biomarkers of disease progression in patients with primary CNS lymphoma. Dr Rubenstein describes the genomic alterations that were identified, including alterations at the (p) arm of chromosome 6 (6p21.3), and mutations in the tumor suppressor genes BTG1 and ETV6. These biomarkers may be used to risk stratify patients and develop personalized therapeutic approaches, and require further investigation. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
